KTS9: exploratory daratumumab pilot
Fluge Ø et al. · 2025 · Frontiers in Medicine
Indexed 2026-11-12.
Reported findings and study design
Reported findings
Single-arm study of subcutaneous daratumumab at a fixed 1,800 mg dose. Patients received repeated injections and were followed for symptoms, physical function and activity.
Dose, route and schedule
Single-arm study of subcutaneous daratumumab at a fixed 1,800 mg dose. Patients received repeated injections and were followed for symptoms, physical function and activity.
Protocol source ↗ · Original source
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Clinical improvement | The authors judged 6/10 participants to have marked clinical improvement during follow-up. | |
| Immunoglobulin levels | Serum IgG declined after treatment. |
The small uncontrolled pilot cannot estimate a placebo-adjusted effect. The randomized follow-up is a separate protocol.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The small uncontrolled pilot cannot estimate a placebo-adjusted effect. The randomized follow-up is a separate protocol.
Related publications may cover the same research program or participants.
Source access
Single-arm study of subcutaneous daratumumab at a fixed 1,800 mg dose. Patients received repeated injections and were followed for symptoms, physical function and activity.
Source reviewed 2026-11-12.
Citation and original source
Original source: Fluge Ø et al.. KTS9: exploratory daratumumab pilot Frontiers in Medicine 2025.
Molekul research summary: https://molekul.io/research/daratumumab-kts9-2025. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry